Overview

Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.
Phase:
Phase 1
Details
Lead Sponsor:
Tracon Pharmaceuticals Inc.
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins